Clinical Trial Update: A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Labvax 3(22)-23 with GM-CSF, alone or in combination with pembrolizumab, in patients with advanced adenocarcinoma; recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Labvax 3(22)-23
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianhong Li | Conditions: Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: RECRUITING